ethyl 3-amino-2-(p-chlorophenyl)-propyl(diethoxymethyl)phosphinate | 103680-68-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3-amino-2-(p-chlorophenyl)-propyl(diethoxymethyl)phosphinate
• 英文别名: ethyl 3-amino-2-(4-chlorophenyl)propyl(diethoxymethyl)phosphinate；ethyl 3-amino-2-(p-chlorophenyl)propyl(diethoxymethyl)-phosphinate；ethyl 3-amino-2-(p-chlorophenyl)propyl(diethoxymethyl)phosphinate；2-(4-chlorophenyl)-3-[diethoxymethyl(ethoxy)phosphoryl]propan-1-amine
• CAS: 103680-68-8
• 化学式: C₁₆H₂₇ClNO₄P
• 分子量: 363.821
• InChiKey: FDPRUUIWTDTXEU-UHFFFAOYSA-N

物化性质

• 沸点：
  446.4±55.0 °C(Predicted)
• 密度：
  1.157±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  23
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  70.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 3-amino-2-(p-chlorophenyl)-propyl(diethoxymethyl)phosphinate 以 盐酸 为溶剂， 反应 1.0h， 以to give 3-amino-2-(4-chlorophenyl)propylphosphonous acid hydrochloride的产率得到3-amino-2-(4-chlorophenyl)propylphosphonous acid hydrochloride
  参考文献：
  名称：

  Substituted propane-phosphonous acid compounds

  摘要：

  式子为 ##STR1## 的化合物，其中R.sup.1、R.sup.2和R.sup.3中的一个代表氢、C.sub.1-.sub.8-烷基、C.sub.3-.sub.6-环烷基、苯基（可选用卤代）、C.sub.1-.sub.4-烷基、C.sub.1-.sub.4-烷氧基和/或三氟甲基，或C.sub.7-.sub.10-苯基烷基（苯基部分可选用卤代）、C.sub.1-.sub.4-烷基、C.sub.1-.sub.4-烷氧基和/或三氟甲基，另外两个为氢，或其盐。这些化合物具有有价值的药物性质。

  公开号：

  US05243062A1
• 作为产物：
  描述：

  1-nitro-2-(4-chlorophenyl)ethylene 在 镍 氢气 、 lithium diisopropyl amide 作用下， 以 乙醇 为溶剂， -78.0~20.0 ℃ 、100.0 kPa 条件下， 反应 1.0h， 生成 ethyl 3-amino-2-(p-chlorophenyl)-propyl(diethoxymethyl)phosphinate
  参考文献：
  名称：

  Diethoxymethylphosphonites and phosphinates. Intermediates for thesynthesis of α,β- and X aminoalkylphosphonous acids

  摘要：

  DOI：

  10.1016/s0040-4020(01)89240-1

文献信息

• Substituted propane-phosphinic acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US05064819A1

  公开（公告）日：1991-11-12

  Compounds of the formula I ##STR1## wherein R denotes an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic or araliphatic radical having 2 or more carbon atoms, and wherein one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen or an aliphatic, cycloaliphatic, araliphatic or aromatic radical, another one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen or, in the case of R.sup.1 and R.sup.2, is hydroxy, and the remaining one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen, or wherein R denotes methyl, R.sub.1 denotes hydrogen or hydroxy, R.sub.2 denotes an aromatic radical and R.sub.3 represents hydrogen, and their salts have GABA.sub.B -antagonistic properties and can be used as GABA.sub.B -antagonists. They are obtained when in a compound of formula II ##STR2## in which R, R.sup.1, R.sup.2 and R.sup.3 have their previous significances, Z represents --NH.sub.2 and R.sup.4 denotes a hydroxy-protective group R.sup.5 or, when R.sup.1 and R.sup.3 denote hydrogen and R.sup.2 denotes hydrogen or alkyl, denotes an alkali metal or ammonium ion R.sup.6, or Z represents a protected or latent amino group Z.sup.0 and R.sup.4 denotes hydrogen or a hydroxy-protective group R.sup.5, any group R.sup.5 or R.sup.6 is replaced by hydrogen, and/or any group Z.sup.0 is converted into --NH.sub.2.

  公式I的化合物##STR1##其中R表示具有2个或更多碳原子的脂肪族、环脂族、环脂族-脂肪族或芳基脂肪基，其中R.sup.1、R.sup.2和R.sup.3中的一个代表氢或脂肪族、环脂族、芳基脂肪基或芳香族基，R.sup.1、R.sup.2和R.sup.3中的另一个是氢或在R.sup.1和R.sup.2的情况下是羟基，而R.sup.1、R.sup.2和R.sup.3中的剩余一个是氢，或者R表示甲基，R.sub.1表示氢或羟基，R.sub.2表示芳基，R.sub.3表示氢，它们的盐具有GABA.sub.B-拮抗性质，可用作GABA.sub.B-拮抗剂。当在公式II的化合物中获得它们##STR2##其中R、R.sup.1、R.sup.2和R.sup.3具有其先前的含义，Z表示--NH.sub.2，R.sup.4表示羟基保护基R.sup.5或者当R.sup.1和R.sup.3表示氢且R.sup.2表示氢或烷基时，表示碱金属或铵离子R.sup.6，或者Z表示受保护或潜在的氨基Z.sup.0且R.sup.4表示氢或羟基保护基R.sup.5，任何一个R.sup.5或R.sup.6基团被氢取代，和/或任何一个Z.sup.0基团被转化为--NH.sub.2。
• Substituted propane-phosphonous acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US04656298A1

  公开（公告）日：1987-04-07

  The compounds of the formula ##STR1## in which one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, C.sub.1-8 -alkyl, C.sub.3-6 -cycloalkyl, phenyl optionally substituted by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluoromethyl, or C.sub.7-10 -phenylalkyl optionally substituted in the phenyl moiety by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluormethyl, and the other two are hydrogen, or salts thereof. These compounds have valuable pharmaceutical properties.

  公式##STR1##中的化合物，其中R.sup.1、R.sup.2和R.sup.3中的一个代表氢、C.sub.1-8-烷基、C.sub.3-6-环烷基、苯基（可选择地被卤素取代）、C.sub.1-4-烷基、C.sub.1-4-烷氧基和/或三氟甲基，或C.sub.7-10-苯基烷基，苯基部分可选择地被卤素、C.sub.1-4-烷基、C.sub.1-4-烷氧基和/或三氟甲基取代，另外两个是氢，或其盐。这些化合物具有宝贵的药用性能。
• Substituted propane-phosphonuous acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US04772738A1

  公开（公告）日：1988-09-20

  The compounds of the formula ##STR1## in which one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, C.sub.1-8 -alkyl, C.sub.3-6 -cycloalkyl, phenyl optionally substituted by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluoromethyl, or C.sub.7-10 -phenylalkyl optionally substituted in the phenyl moiety by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluormethyl, and the other two are hydrogen, or salts thereof. These compounds have valuable pharmaceutical properties.

  式子为##STR1##的化合物，其中R.sup.1、R.sup.2和R.sup.3中的一个代表氢，C.sub.1-8-烷基，C.sub.3-6-环烷基，苯基，该苯基可选用卤代基，C.sub.1-4-烷基，C.sub.1-4-烷氧基和/或三氟甲基，或C.sub.7-10-苯基烷基，该苯基烷基中的苯基可选用卤代基，C.sub.1-4-烷基，C.sub.1-4-烷氧基和/或三氟甲基，而另外两个是氢，或其盐。这些化合物具有有价值的药物特性。
• Dingwall, J. G.; Ehrenfreund, J.; Hall, R. G., Phosphorus and Sulfur and the Related Elements, 1987, vol. 30, p. 571 - 574
  作者：Dingwall, J. G.、Ehrenfreund, J.、Hall, R. G.、Jack, J.

  DOI：——

  日期：——
• Phosphinic Acid Analogs of GABA. 2. Selective, Orally Active GABAB Antagonists
  作者：Wolfgang Froestl、Stuart J. Mickel、Georg von Sprecher、Peter J. Diel、Roger G. Hall、Ludwig Maier、Dietrich Strub、Vito Melillo、Peter A. Baumann

  DOI：10.1021/jm00017a016

  日期：1995.8

  In 1987, 25 years after the synthesis of the potent and selective GABA(B) agonist baclofen (1), Kerr et al.(5) described the first GABA(B) antagonist phaclofen 2. However, phaclofen and structurally similar derivatives 3-5 did not cross the blood-brain barrier and hence were inactive in vivo as central nervous system agents. As a consequence, the therapeutic potential of GABA(B) antagonists remained unclear. In exploring GABA and baclofen derivatives by replacing the carboxylic acid residue with various phosphinic acid groups, we discovered more potent and water soluble GABA(B) antagonists. Electrophysiological experiments in vivo demonstrated that some of the new compounds were capable of penetrating the blood-brain barrier after oral administration. Neurotransmitter release experiments showed that they interacted with several presynaptic GABA(B) receptor subtypes, enhancing the release of GABA, glutamate, aspartate, and somatostatin. The new GABA(B) antagonists interacted also with postsynaptic GABA(B) receptors, as they blocked late inhibitory postsynaptic potentials. They facilitated the induction of long-term potentiation in vitro and in, vivo, suggesting potential cognition enhancing effects. Fifteen compounds were investigated in Various memory and learning paradigms in rodents. Although several compounds were found to be active, only 10 reversed the age-related deficits of old rats in a multiple-trial one-way active avoidance test after chronic treatment. The cognition facilitating effects of 10 were confirmed in learning experiments in Rhesus monkeys. The novel GABA(B) antagonists showed also protective effects in various animal models of absence epilepsy.